Compare Mesoblast Limited (MESO) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Nutanix Inc — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while Nutanix Inc trades at $54.8 (market cap $14.90B). The key difference: Nutanix Inc is far larger — about 6.9× Mesoblast Limited's market cap. Which is the better fit depends on your goals.
| MESO | NTNX | |
|---|---|---|
Market Cap | $2.17B | $14.90B |
Sector | Technology | Technology |
52-Week High | $20.96 | $81.12 |
52-Week Low | $12.88 | $34.41 |
Enterprise Value | $2.17B | $14.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Nutanix (NTNX) trades at $55.11, showing minimal daily change. The stock exhibits a bullish technical trend, supported by strong earnings beats in recent quarters, including Q1 2026 EPS of $0.47 versus $0.36 expected. Revenue growth is projected to increase from $2.54 billion in 2025 to $2.7 billion in 2026, with net income margin improving to 10.03%. Positive sentiment is fueled by recent news, such as the NVIDIA certification for its Unified Storage solution, highlighting its position in AI infrastructure.
The outlook for NTNX is positive, driven by consistent earnings outperformance and strategic positioning in hybrid multicloud and AI markets. Key opportunities include expanding profit margins and leveraging partnerships. Risks involve competitive pressures in cloud computing and reliance on enterprise spending. The consensus analyst price target of $57.80 suggests moderate upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
